Chronic kidney disease-mineral and bone disorder (CKDMBD) is common in kidney transplant recipients (KTRs), where secondary hyperparathyroidism (HPTH) and posttransplantation bone disease (PTBD) are potential effectors of both graft and vascular aging. Reduced 25(OH)D levels are highly prevalent in KTRs. Experimental and clinical evidence support the direct involvement of deranged vitamin D metabolism in CKD-MBD among KTRs. This review analyzes the pathophysiology of vitamin D derangement in KTRs and its fall out on patient and graft outcome, highlighting the roles of both nutritional and active vitamin D compounds to treat PTBD, cardiovascular disease (CVD) and graft dysfunction. Fibroblast growth factor-23-parathyroid hormone (PTH)-vitamin D axis, immunosuppressive therapy and previous bone status have been associated with PTBD. Although several studies reported reduced PTH levels in KTRs receiving nutritional vitamin D, its effects on bone mineral density (BMD)

Cianciolo, G., Galassi, A., Capelli, I., Angelini, M.l., La Manna, G., Cozzolino, M. (2016). Vitamin D in Kidney Transplant Recipients: Mechanisms and Therapy. AMERICAN JOURNAL OF NEPHROLOGY, 43(6), 397-407 [10.1159/000446863].

Vitamin D in Kidney Transplant Recipients: Mechanisms and Therapy

CIANCIOLO, GIUSEPPE;CAPELLI, IRENE;ANGELINI, MARIA LAURA;LA MANNA, GAETANO;
2016

Abstract

Chronic kidney disease-mineral and bone disorder (CKDMBD) is common in kidney transplant recipients (KTRs), where secondary hyperparathyroidism (HPTH) and posttransplantation bone disease (PTBD) are potential effectors of both graft and vascular aging. Reduced 25(OH)D levels are highly prevalent in KTRs. Experimental and clinical evidence support the direct involvement of deranged vitamin D metabolism in CKD-MBD among KTRs. This review analyzes the pathophysiology of vitamin D derangement in KTRs and its fall out on patient and graft outcome, highlighting the roles of both nutritional and active vitamin D compounds to treat PTBD, cardiovascular disease (CVD) and graft dysfunction. Fibroblast growth factor-23-parathyroid hormone (PTH)-vitamin D axis, immunosuppressive therapy and previous bone status have been associated with PTBD. Although several studies reported reduced PTH levels in KTRs receiving nutritional vitamin D, its effects on bone mineral density (BMD)
2016
Cianciolo, G., Galassi, A., Capelli, I., Angelini, M.l., La Manna, G., Cozzolino, M. (2016). Vitamin D in Kidney Transplant Recipients: Mechanisms and Therapy. AMERICAN JOURNAL OF NEPHROLOGY, 43(6), 397-407 [10.1159/000446863].
Cianciolo, G; Galassi, A; Capelli, I; Angelini, Ml; La Manna, G; Cozzolino, M.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/590507
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 40
social impact